Sonoma Pharmaceuticals, INC DEF 14A proxy statements

Sonoma Pharmaceuticals, Inc. has issued its proxy statement for the 2026 Annual Stockholders Meeting, scheduled for September 16, 2026, detailing proposals for director elections, executive compensation, and auditor ratification.

Sonoma Pharmaceuticals, Inc. is holding a special meeting of stockholders on June 24, 2026, to vote on a proposal to reincorporate the company from Delaware to Nevada, citing potential cost savings and enhanced director/officer liability protections.

Sonoma Pharmaceuticals, Inc. has released its definitive proxy statement outlining proposals for its 2025 Annual Stockholders Meeting, including director election, advisory vote on executive compensation, and auditor ratification, alongside detailed compensation and governance disclosures.

Sonoma Pharmaceuticals is actively seeking stockholder participation for a crucial proposal requiring a quorum at the upcoming Annual Meeting on August 23, 2024.

Sonoma Pharmaceuticals has adjourned its Annual Meeting of Stockholders until August 23, 2024, due to the absence of a quorum.

Sonoma Pharmaceuticals is urging stockholders to vote their shares promptly for the upcoming annual meeting on August 14, 2024, emphasizing the importance of achieving a quorum.

Sonoma Pharmaceuticals is asking stockholders to vote on key proposals including reincorporation in Nevada, increasing authorized shares, and a potential reverse stock split at its upcoming annual meeting.